Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb reports positive Baraclude results

Bristol-Myers Squibb reports positive Baraclude results

5th November 2007

Bristol-Myers Squibb has announced the results of a four-year clinical study of Baraclude (entecavir), a nucleoside analogue indicated as a treatment of chronic hepatitis B infection in adults.

Trial results showed that 91 per cent of patients administered with Baraclude exhibited a suppression in hepatitis B virus levels in the blood to undetectable levels when measured at week 192 of treatment.

Safety results from the study, presented to the annual meeting of the American Association for the Study of Liver Diseases, were consistent with previous experience, with five deaths reported, none of which were attributed to the compound.

Hugo Cheinquer, of Universidade Federal Do Rio Grande Do Sul, Porto Alegre in Brazil, said: “The data indicate that Baraclude maintained viral suppression through four years of treatment in this patient population.”

He added that the majority of patients receiving the compound showed an undetectable viral load at four years, with one patient developing resistance – results he described as encouraging for physicians in the field.

In May 2007, Bristol-Myers Squibb announced the results of the ETV-079 study, with improved viral load reduction at 12, 24 and 48 weeks for Baraclude when compared to adefovir.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.